Design And Evaluation Of Teneligliptin Tablet

Teneligliptin Tablet
Ritu Chauhan 1 India , Anuradha Verma 1 India , Tushar Singhal 1 India , Anshika Garg 1 India , Babita Kumar 1 India , Dayanidhi Pandey 2 India
1 Sanskar College Of pharmacy and Research
2 Himachal Pradesh, India
Link Copied!
Published 2023-06-27
Vol. 5 No. 1 (2023) PAGES 89-100
DOI 10.36566/ijhsrd/Vol5.Iss1/153
Views / Downloads 846 1134

Background : Excessive workload, stress, and, genetic disorders are the main reason for the increasing prevalence of Type II diabetes in India. Teneligliptin, is a potent Dipeptidyl peptidase (DPP-4) inhibitor that exerts its action in Type II diabetes mellitus. Teneligliptin mainly acts by increasing insulin levels and decreasing glucagon levels in the circulation in a glucose-dependent manner. It offers sufficient glycemic control in a period of 12 weeks ad is also tolerable by renal-impaired patients.

Methods: Six formulations of teneligliptin tablets were prepared by using different ratios of MCC, maize starch, HPMC, HPC, aerosol, and magnesium stearate. The prepared tablets were evaluated in terms of friability, hardness, disintegration, and dissolution rate profile

Results: Out of all six formulations, F4 reflects better tablet characteristics as compared to the rest five formulations

Conclusions: F4 turns out to be the best formulation of the present study and can be used for commercial production.

Design And Evaluation Of Teneligliptin Tablet: Teneligliptin Tablet. (2023). INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 5(1), 89-100. https://doi.org/10.36566/ijhsrd/Vol5.Iss1/153
Download data is not yet available.
  1. Tripathi KD. Essentials of medical pharmacology. JP Medical Ltd; 2013
  2. Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handbook of clinical neurology. 2014 Jan 1;126:211-22. Doi: https://doi.org/10.1016/B978-0-444-53480-4.00015-1
  3. Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. Diabetes: an old disease, a new insight. 2013:1-1. Doi: https://doi.org/10.1007/978-1-4614-5441-0_1
  4. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman medical journal. 2012 Jul;27(4):269. Doi: 10.5001/omj.2012.68
  5. Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013 Sep 30;4(4):46-57. Doi: 10.5897/JPAP2013.0001
  6. Atlas D. International diabetes federation. IDF Diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation. 2015;33:2.
  7. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC. Type 2 diabetes mellitus. Nature reviews Disease primers. 2015 Jul 23; 1(1):1-22. Doi: https://doi.org/10.1038/nrdp.2015.19
  8. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences. 2020 Jan;21(17):6275. Doi: https://doi.org/10.3390/ijms21176275
  9. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, metabolic syndrome and obesity: targets and therapy. 2013 May 6:187-95.
  10. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes, metabolic syndrome and obesity: targets and therapy. 2016 Aug 16:251-60
  11. Maladkar M, Sankar S, Kamat K. Teneligliptin: heralding change in type 2 diabetes. Journal of Diabetes mellitus. 2016;6(02):113.Doi: 10.4236/jdm.2016.62012
  12. Lachman L, Liberman HA, Kanig JL, Textbook of The theory and practice of industrial pharmacy Lea & Febiger, Philadelphia;1989
  13. Agrawal R, Naveen Y. Pharmaceutical processing–A review on wet granulation technology. Int J Pharm frontier res. 2011 Apr;1(1):65-83.
  14. Kristensen HG, Schaefer T. Granulation: a review on pharmaceutical wet-granulation. Drug development and industrial pharmacy. 1987 Jan 1;13(4-5):803-72. Doi: https://doi.org/10.3109/03639048709105217
  15. Thapa P, Tripathi J, Jeong SH. Recent trends and future perspective of pharmaceutical wet granulation for better process understanding and product development. Powder Technology. 2019 Feb 15;344:864-82. Doi: https://doi.org/10.1016/j.powtec.2018.12.080
  16. Tiwari P. Formulation and Evaluation of SR Tablets of Anti-diabetic drug Gliclazide. Hemke AT, Ghuge YG, Gupta KR. Application of RP-HPLC and UV-Spectrophotometric Method in Dissolution Testing of Teneligliptin. Der Pharma Chemica. 2018;10(1):103-.10
  17. Gopinath R, Naidu RA. Pharmaceutical preformulation studies–current review. International Journal of Pharmaceutical and Biological Archives. 2011;2(5):1391-400.
  18. Parashar B, Chauhan A, Prashar D, Chandel A, Kumar H, Purohit R. Formulation and evaluation aspects of tablets-An overview. Am J PharmTech Res. 2012;2:2249-3387
  19. Chaurasia G. A review on pharmaceutical preformulation studies in formulation and development of new drug molecules. Int J Pharm Sci Res. 2016 Jun 1;7(6):2313-20.
  20. Nyol S, Gupta MM. Immediate drug release dosage form: a review. Journal of Drug Delivery and Therapeutics. 2013 Mar 15;3(2).
  21. Chaturvedi H, Garg A, Rathore US. Post-compression evaluation parameters for tablets-an overview. Eur J Pharm Med Res [Internet]. 2017;4(11):526-30.
  22. Jain S.K & Soni V. “Bentley; Textbook of Pharmaceutics” Published by Elsevier India Private Limited, 309
  23. Kushwaha. P “Hand book of Pharmaceutical Technology” Ist Edition 2015, Published by Jaypee Publication.
  24. Javed Ali, A Ahuja and R.K Khar, Text book of Dosage Form Design, Birla publication Pvt. Ltd. New Delhi, India, 2006; P01-31.
  25. Tiwari P. Formulation and Evaluation of SR Tablets of Anti-diabetic drug Gliclazide.
  26. Godge GR. Formulation development and in-vitro evaluation of sustained release tablets of telmisartan by solid dispersion technology. Asian J of PharmTech & Inn. 2016; 4:17.
  27. Amit MS, Kiran KD, Varsha AR. A simple UV spectrophotometric method development and validation of Teneligliptin in tablet dosage form. Indo Am J Pharm Res. 2016;6(04):14-21.
  28. Azarmi S, Roa W, Löbenberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. International Journal of pharmaceutics. 2007 Jan 2; 328(1):12-21. Doi: https://doi.org/10.1016/j.ijpharm.2006.10.001
  29. Silva DA, Webster GK, Bou-Chacra N, Löbenberg R. The significance of disintegration testing in pharmaceutical development. Dissolution Technol. 2018 Aug 1; 25(3):30-8. Doi: dx.doi.org/10.14227/DT250318P30
  30. Markl D, Zeitler JA. A review of disintegration mechanisms and measurement techniques. Pharmaceutical research. 2017 May;34(5):890-917. Doi: https://doi.org/10.1007/s11095-017-2129-z

Copyright (c) 2023 INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD)

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright Rights & Permissions Guide

Reproducing Published Material from other Publishers

It is absolutely essential that authors obtain permission to reproduce any published material (figures, schemes, tables or any extract of a text) which does not fall into the public domain, or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).

Permission is required for:

  1. Your own works published by other Publishers and for which you did not retain copyright.
  2. Substantial extracts from anyones’ works or a series of works.
  3. Use of Tables, Graphs, Charts, Schemes and Artworks if they are unaltered or slightly modified.
  4. Photographs for which you do not hold copyright.

Permission is not required for:

  1. Reconstruction of your own table with data already published elsewhere. Please notice that in this case you must cite the source of the data in the form of either “Data from…” or “Adapted from…”.
  2. Reasonably short quotes are considered fair use and therefore do not require permission.
  3. Graphs, Charts, Schemes and Artworks that are completely redrawn by the authors and significantly changed beyond recognition do not require permission.

Obtaining Permission

In order to avoid unnecessary delays in the publication process, you should start obtaining permissions as early as possible. If in any doubt about the copyright, apply for permission. JNH cannot publish material from other publications without permission.

The copyright holder may give you instructions on the form of acknowledgement to be followed; otherwise follow the style: “Reproduced with permission from [author], [book/journal title]; published by [publisher], [year].’ at the end of the caption of the Table, Figure or Scheme.

Every mansucript should be accompanied by "Copyright Transfer Agreement" prior to the article publication

Dimension Badge

Downloads

Downloads
Crossmark Badge
Crossmark Badge
Section
Articles
Keywords
Teneligliptin Diabetes mellitus glycemic control disintegration formulation insulin

Similar Articles

51-60 of 60

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)